CABLIVI

sanofi-aventis canada inc🇨🇦 Health Canada

Approval Id: 04f03dd67c64d61a
Drug Approval Canada Name: CABLIVI
Product Name: CABLIVI
Status: Cancelled Post Market
Status Date: 2025-01-14
Original Market Date: 2020-09-04
Din: 02496194
Drug Class: Human
Dosage Form: Powder For Solution , Kit
Route Of Administration: Subcutaneous , Intravenous
Schedule: Schedule D , Prescription
Ahfs: 20:12.92
Atc Original: B01AX07 CAPLACIZUMAB
Atc Name: b 01 ax 07
Aig Number: 0162033001
Company Name: sanofi-aventis canada inc
Company Address: 1755 Steeles Avenue West, Toronto, Ontario, Canada, M2R 3T4

CAPLACIZUMAB

11 MG / VIAL

Authorized

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

04f03dd67c64d61a

Type

Standard